Ardevora Asset Management LLP bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 158,120 shares of the company’s stock, valued at approximately $34,461,000. Ardevora Asset Management LLP owned about 0.18% of IDEXX Laboratories as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently modified their holdings of IDXX. Signaturefd LLC bought a new position in shares of IDEXX Laboratories during the first quarter worth $105,000. Three Peaks Capital Management LLC bought a new position in shares of IDEXX Laboratories during the first quarter worth $108,000. Optimum Investment Advisors bought a new position in shares of IDEXX Laboratories during the first quarter worth $139,000. Cerebellum GP LLC bought a new position in shares of IDEXX Laboratories during the second quarter worth $181,000. Finally, Financial Gravity Wealth Inc. bought a new position in shares of IDEXX Laboratories during the first quarter worth $191,000. Hedge funds and other institutional investors own 86.27% of the company’s stock.
In other news, Director William T. End sold 9,470 shares of the stock in a transaction on Thursday, May 10th. The shares were sold at an average price of $208.36, for a total value of $1,973,169.20. Following the sale, the director now owns 31,786 shares of the company’s stock, valued at $6,622,930.96. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Jacqueline Studer sold 475 shares of the stock in a transaction on Wednesday, May 30th. The shares were sold at an average price of $209.98, for a total transaction of $99,740.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 11,571 shares of company stock worth $2,405,215. 2.56% of the stock is owned by insiders.
A number of brokerages recently weighed in on IDXX. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $255.00 target price for the company in a research report on Monday, June 18th. Canaccord Genuity reaffirmed a “positive” rating and set a $215.00 price target on shares of IDEXX Laboratories in a research note on Monday, May 7th. ValuEngine raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Wednesday, May 2nd. BidaskClub downgraded shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 9th. Finally, Credit Suisse Group upped their price target on shares of IDEXX Laboratories from $209.00 to $228.00 and gave the company an “outperform” rating in a research note on Friday, June 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Buy” and a consensus target price of $232.00.
IDEXX Laboratories traded down $3.51, reaching $237.76, during mid-day trading on Monday, MarketBeat Ratings reports. 32,733 shares of the company’s stock traded hands, compared to its average volume of 374,853. The company has a market cap of $20.96 billion, a price-to-earnings ratio of 72.45, a PEG ratio of 2.21 and a beta of 0.67. The company has a quick ratio of 0.72, a current ratio of 0.96 and a debt-to-equity ratio of -12.43. IDEXX Laboratories, Inc. has a 12-month low of $146.09 and a 12-month high of $252.49.
IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Friday, May 4th. The company reported $1.01 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.92 by $0.09. The company had revenue of $537.60 million for the quarter, compared to the consensus estimate of $525.14 million. IDEXX Laboratories had a net margin of 13.87% and a negative return on equity of 530.24%. IDEXX Laboratories’s revenue was up 16.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.77 earnings per share. equities research analysts anticipate that IDEXX Laboratories, Inc. will post 4.17 earnings per share for the current fiscal year.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Story: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.